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cell-penetrating peptide(s); Dap, diaminopropionic acid; DEP, 7-diethylamino-2-oxo-2H-
chromen-3-carboxylic acid; DMP, (7-Dimethylamino-2-oxo-2H-chromen-4-yl) acetic acid; 
DNS, dansyl; EMEM, Earle’s modified minimal essential medium; ER, endoplasmic 
reticulum; Fe(HQ)3, iron(III)-8-hydroxyquinoline; Fe-NTA, Fe-nitrilotriacetate; HBL,  Nε-
2.3-dihydroxybenzoyllysine; HPO, 3-hydroxypyridin-4-one; HRMS, high resolution mass 
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oxygen species; RPA, rhodamine B-[(1,10-phenanthrolin-5-yl)aminocarbonyl] benzylester ; 
RP-HPLC, reverse phase HPLC; RT, room temperature; SAR, structure-activity relationship; 
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Summary Statement: This work introduces novel fluorescent iron chelator-peptides that 
specifically target mitochondria and sense changes in labile iron levels of the organelle, 
which is detrimental in oxidative stress and pathological conditions. 
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ABSTRACT 
 
Mitochondrial labile iron (LI) plays a crucial role in oxidative injuries and 
pathologies. At present, there is no organelle-specific sensitive iron sensor which can reside 
exclusively in the mitochondria and reliably monitor levels of LI in this organelle. Here we 
describe the development of novel fluorescent and highly specific mitochondria iron sensors, 
using the family of mitochondrial-homing ‘SS-peptides’ (short cell permeable signal peptides 
mimicking mitochondrial import sequence) as carriers of highly specific iron chelators for 
sensitive evaluation of the mitochondrial LI. Microscopic analysis of subcellular localization 
of a small library of fluorescently labelled SS-like peptides identified dansyl (DNS) as the 
lead fluorophore for the subsequent synthesis of chimeric iron chelator-peptides of either 
catechol (compounds 10 and 11) or hydroxypyridinone (compounds 13 and 14) type. The 
iron-sensing ability of these chimeric compounds was confirmed by fluorescent quenching 
and de-quenching studies both in solution and in cells, with compound 13 exhibiting the 
highest sensitivity towards iron modulation. The intramolecular fluorophore-chelator distance 
and the iron affinity both influence probe sensitivity towards iron. These probes represent the 
first example of highly sensitive mitochondria-directed fluorescent iron chelators with 
potential to monitor mitochondrial LI levels. 
 
 
INTRODUCTION 
 
The primary function of mitochondria is to support aerobic respiration and to generate 
the energy providing substrate, ATP [1]. Given this fundamental role, defects in 
mitochondrial function have serious physiological consequences. Abnormalities of 
mitochondrial DNA and oxidative phosphorylation have been identified in several diseases 
[1, 2]. 
Recently, mitochondria have been recognized as a principal destination of non 
protein-bound labile (and chelatable) iron called LI [3]. This redox active mitochondrial 
labile iron pool (LIP) acts as a catalyst in the formation of reactive oxygen species (ROS) via 
Fenton chemistry, thereby making these organelles particularly sensitive to oxidative stress 
seen under certain pathological conditions and leading to cell damage and death [4, 5]. It has 
been hypothesized that excessive levels of the mitochondrial LIP due to, for instance, defects 
in iron-sulfur cluster synthesis and function, may result in aging, with disease consequences 
which have implications particularly in the more common forms of neurodegeneration, 
namely Friedreich’s ataxia, Parkinson’s disease and Alzheimer’s disease [6-11]. 
Despite increased deposits of iron having been reported in some of these diseases, 
monitoring the concentration of mitochondrial LIP both under physiological and pathological 
conditions has so far proven difficult. Currently there is no mitochondria-specific sensitive 
iron sensor which can reliably monitor levels of LIP in this organelle. To our knowledge, 
rhodamine B-[(1,10-phenanthrolin-5-yl)aminocarbonyl] benzylester (RPA) is the only iron-
sensitive probe that targets to mitochondria and does so potentiometrically. However the 
iron-chelating moiety ‘phenanthrolin’ is not highly specific for iron and in cellular studies, it 
has been difficult to accurately estimate the level of mitochondrial LIP due to failure to 
reverse the iron-mediated quenching of RPA by highly specific and potent iron chelators [4]. 
The development of a selective mitochondrial iron sensor would therefore present an 
important stepping-stone in the monitoring and adjustment of mitochondrial LIP. 
The targeted delivery of biochemical agents to the mitochondria has been shown to 
enhance both their pharmacological effects and therapeutic window when compared to 
simple compound delivery [12]. Several pharmaceutical and biotechnological strategies have 
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been described to address this challenge. For example, conjugation of bioactive drugs, 
primarily antioxidants, to triphenylphosphonium cations (TPP) allowed selective 
accumulation into mitochondria, in a membrane potential-driven mechanism both for cell-
penetration and for inner mitochondrial membrane accumulation [13-15]. 
We have focused our attention on the class of small “SS peptides”, which selectively 
target mitochondria [16-19]. Such peptides are amphiphilic, contain alternating aromatic and 
basic groups, and despite carrying several positive charges, are able to freely penetrate 
membranes in a non-saturable manner and to rapidly accumulate in the mitochondria [20, 
21]. Importantly, they are also able to pass the blood brain barrier. Such mitochondria-
directed peptides, as well as some newly-described cationic and lipophilic peptides [22, 23] 
have been used successfully as carriers of functional molecules (including antioxidants or 
drugs) to the mitochondria [24-31]. 
Here, we report the development of selective mitochondrial LI sensors. Using a 
library of fluorescent mitochondria-targeted amphiphilic tetra- and penta-peptides, we 
identified a lead compound for the subsequent synthesis of a set of iron chelator-peptides on 
the basis of selectivity for mitochondrial localization, as determined by fluorescence 
microscopy. The analysis of the biological trafficking of the compounds highlighted the 
influence of dye structure on mitochondria localization. A panel of three novel iron chelator-
peptides was synthesized which demonstrated sensitive responsiveness to iron, both in cell-
free systems and cells. This study has provided a comprehensive investigation of the 
organelle selectivity and functionality of this novel class of chimeric cell-penetrating peptides 
(CPPs) and paves the way in the development of selective mitochondrial biosensors for the 
monitoring of mitochondria-related diseases. 
 
 
EXPERIMENTAL 
 
Peptide Synthesis  
See Supplementary Information for protocols and characterization information. 
 
Analytical  
High resolution mass spectrometry (HRMS) was conducted on an Exactive Plus Orbitrap 
Mass Spectrometer. Analytical reverse phase-HPLC (RP-HPLC) was conducted on a HP1050 
HPLC system equipped with an autosampler, a quaternary pump and a Diode-Array Detector. 
A Kinetex 2.6 m XB-C18 100A (150 x 2.1 mm) column was employed. The flow rate was 
0.2 mL min-1 and the eluents were monitored at wavelengths between 214-281 nm. A linear 
gradient of mobile phase B [acetonitrile (ACN) containing 0.1% trifluoroacetic acid (TFA)] 
over mobile phase A (0.1% TFA in water) from 0-90% B in 30 min was performed. Data 
were collected and analyzed using ChemStation software. Semipreparative RP-HPLC was 
conducted on a Waters SymmetryPrep™ C8, 7 μm, 19 x 300 mm column using water/ACN 
gradients at a flow rate of 7 mL min-1. The pKa and clogD7.4 values were calculated using 
MarvinView 6.1.3 software. The net charge values were obtained using the calculated pKa 
values as reference using HySS2009 software. 
 
Cell culture  
The human primary foreskin fibroblast (FEK4) cells (kindly provided by Prof. R. M. Tyrrell, 
University of Bath, UK) were grown as previously described [32], except that phenol red-free 
culture medium was used. For experiments involving peptide delivery followed by 
microscopy, cells were seeded on glass coverslips and grown for 2-3 days in 
Ac
ce
pte
d M
an
us
cri
pt
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
    Abbate et al 
4 
 
penicillin/streptomycin-free medium in order to reach a confluency of 60-70% on the day of 
microscopy analysis. 
 
Peptide delivery 
Cells grown on coverslips were rinsed twice with serum-free medium, incubated with 
peptides at a concentration of 1-30 μM for 2 h-overnight at 37 oC in a humidified chamber 
and rinsed as before. An organelle-specific marker was then added for 30 min. Following 
rinsing steps, the coverslips were inverted wet on a glass slide just before live cell 
microscopy analysis. The peptides were prepared from powder as 50-100 mM stocks in 
DMSO, kept at 4 oC and diluted freshly on the day of experiment in warm serum- and phenol 
red-free Earle’s modified minimal essential medium (EMEM) to the concentration required. 
The organelle-specific markers MitoTracker® Deep Red FM (excitation 644 nm/emission 
665 nm), LysoTracker® Deep Red (excitation 647 nm/emission 668 nm) and ER-Tracker™ 
Red (excitation 587 nm/emission 615 nm) were prepared and used according to 
manufacturers’ recommendations. 
 
Live cell microscopy  
Subcellular localization of the DNS- (compounds 3, 4, 10-11 and 13-14) and anthraniloyl 
(ATN)- (compound 2) labelled peptides was analysed on an Olympus IX51 inverted 
epifluorescence microscope equipped with a 100 W mercury UV lamp. Cells were imaged 
with a 40x objective. Images were acquired via an Olympus DP72 digital camera controlled 
by Olympus cell^P Analysis Image Processing software (Soft Imaging System GmbH, 
Muenster, Germany). For the subcellular localization of the [(7-Dimethylamino-2-oxo-2H-
chromen-4-yl) acetic acid] (DMP)- (compounds 5-7) and 7-diethylamino-2-oxo-2H-chromen-
3-carboxylic acid (DEP)- (compounds 8-9) labelled peptides, a Zeiss LSM510META 
inverted confocal microscope equipped with 405 nm blue diode laser, green and red HeNe 
lasers (543 and 633 nm lines) was used. Cells were imaged with a 63x oil objective. 1-2 μm 
thick optical slices were collected and processed using the LSM510 software from Zeiss. 
Cells showing yellow staining, resulting from superimposition of the peptide-specific green 
signal and the organelle-specific red signal, were qualitatively considered positive for 
colocalization. The co-occurence in the images, of green and red fluorescent signals above a 
threshold level was further confirmed by analysis of intensity profiles collected across cells 
(over a length of ca 30-60m) using Image Examiner (from Zeiss) and cell^P (from 
Olympus) Image Processing softwares. The extent of colocalization of each compound with 
mitochondria, lysosomes or endoplasmic reticulum compartments was also measured 
quantitatively by Manders’ correlation coefficients (MCCs) M1 and M2 using ImageJ 
software with the JaCoP plug-in [33, 34] from a random selection of image fields. MCCs 
provide a measure of how much of the signal intensity of a channel occurs in the same 
location as the other channel. Thus M1 represents the extent of overlap of compound signal 
(green) with the organelle signal (red), whereas M2 represents the amount of organelle signal 
overlapping the compound signal. MCCs values range from zero (uncorrelated distributions 
of two probes with one another) to one (fully correlated distributions  of two probes). MCCs 
were chosen instead of the Pearson’s colocalization coefficient as they are particularly well 
suited when the fluorescent signals distribute to different types of compartments [35]. 
 
Fluorescence quenching/dequenching assays  
Cell-free system: Quenching experiments were carried out as described previously [36]. In-
cell studies: Responsiveness of fibroblasts FEK4 cells to iron was achieved by loading them 
with iron(III)-8-hydroxyquinoline [Fe(HQ)3] which was prepared freshly by mixing a 
solution of ferric chloride (10 mM) in water with 8-hydroxyquinoline (30 mM) in DMSO so 
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as to obtain a Fe:ligand ratio of 1:3. The complex was then allowed to form for 1 h at 37 oC 
before use on cells. Briefly, FEK4 cells were first incubated (or not) overnight, with 30 μM 
compound 10-11 and 13-14. The next day, the medium was removed, the cells washed twice 
with PBS, trypsinized, resuspended in buffer F (10 mM HEPES pH 7.3, 150 mM NaCl) and 
counted. 106 cells were transferred to a thermostated (37 oC) quartz cuvette and kept in 
suspension for fluorescence reading with a Kontron spectrofluorimeter (SFM 25, Eching, 
Germany). Fluorescence was monitored until a stable signal was obtained, upon which iron 
was added in 0.6-1 L increments as Fe(HQ)3 complex and fluorescence monitored until a 
stable signal was obtained before the next addition of iron. The cumulative iron(III) 
concentrations were: 0, 0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.5, 3, 4.5 and 6 M. Dequenching of 
fluorescence was achieved by adding deferiprone as a 100 M bolus to the iron-loaded cells. 
PBS, buffer F and the quartz cuvette were all chelex-treated so as to avoid unwanted 
quenching of compounds’ fluorescence. 
 
 
RESULTS 
 
Design and synthesis of the fluorescent mitochondria-targeted peptides 
In the present study, we initially designed and synthesized a series of “SS-like” 
peptides (see Supplementary data, Figure S1) that were similar in size, but differed in the 
nature of the fluorophore attached to them, with the view to select a dye that would not 
interfere with mitochondrial homing of the peptide and with spectroscopic properties that 
would permit analysis by microscopy. For this purpose, the fluorescent probes chosen were 
small in size, on the assumption that larger and bulkier fluorophores, such as the commonly 
used carboxyfluorescein and rhodamine dyes, could perturb the biological behaviour of the 
relatively small conjugates. 
The generic approach for the design of the compound library is illustrated in Figure 1a 
and the sequences and some physicochemical parameters of the synthesized “SS-like” 
peptides are presented in Table 1. The peptides were amidated at the C-terminus and 
incorporated a D-arginine residue in order to increase the peptide stability towards hydrolase 
enzymes. The compounds were prepared using an orthogonal Fmoc-solid-phase peptide 
synthesis (SPPS) method, as summarized in Scheme S1 (Supplementary data). This approach 
was chosen due to its chemical flexibility, efficient peptide preparation and higher safety 
when compared to the di-tert-butyl dicarbonate (Boc) method, which employs toxic 
chemicals such as HF. Crude peptides were purified via semi-preparative HPLC and 
characterized via analytical HPLC and HRMS (see Supplementary data, Table S1). 
Compound 1 is the simplest, non-fluorescent compound which was prepared as a 
control molecule for biophysical evaluation (Table 1). Compound 2 contains an ATN 
fluorophore, compounds 3 and 4 a DNS fluorophore, compounds 5-7 a DMP fluorophore and 
compounds 8-9 a DEP fluorophore (Table 1). Since all the fluorescent tetra-peptides possess 
a predicted charge at neutral pH of approximately +2, we also prepared five-amino acid 
variants of the DNS, DMP and DEP compounds, possessing a charge of +3 at pH 7.4 in order 
to evaluate the effect of net charge on their biological trafficking and behaviour (Table 1). 
Compound 7 displays a DMP fluorophore conjugated to a lysine, rather than a 
diaminopropionic acid (Dap) residue, in order to assess the influence of the fluorescently 
labelled amino acid (and the consequent difference in peptide hydrophobicity) on its 
mitochondria-homing properties. 
 
Intracellular distribution of the fluorescent peptides synthesized 
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Subcellular distribution of the fluorescent peptides was examined using microscopy 
on live human skin fibroblast cells in culture and co-labelling with fluorescent commercial 
markers specific for mitochondria, lysosomes and endoplasmic reticulum (ER), respectively 
(see Experimental section). Throughout the study, colocalization of the peptides and chelator-
peptides to specific organelles was first evaluated qualitatively i) by the occurrence of  
composite fluorescent yellow signal generated by the co-occurrence of both green and red 
fluorescent signals above a threshold level and ii) intensity profile comparison as described in 
Experimental section (see Figures S4 and S5 in Supplementary data). The extent of 
colocalization of the fluorescent peptides to specific organelles was then investigated 
quantitatively using ImageJ software with the JaCoP plug-in to determine Manders’ 
correlation coefficients (MCC) M1 (green/red) and M2 (red/green) (See Experimental section 
and Figure S6). 
The overall analysis of the DMP-labelled compounds 5-7 (see example of compound 
5 in Figures 2a, D and E; S4, D and S6, M1) and the two DEP-labelled compounds 8-9 (data 
not shown) unexpectedly showed no detectable mitochondrial localization. Addition of a 
lysine residue to compound 5 and 9, forming compound 6 and 8 respectively, in an attempt to 
improve mitochondria specificity and membrane permeation, did not cause any visible 
change in cellular distribution (data not shown). None of the DMP- (see example of 
compound 5 in Figures2a, N and O; S4, N and S6, M1) or the DEP-peptides (data not shown) 
localized to the ER compartment. However, some colocalization with lysosomes could be 
observed in a small proportion of cells incubated with compound 5 (Figures 2a, I and J; S4, I 
and S6, M1) and the DEP-peptides (data not shown). In contrast to the DMP- and DEP-
peptides, the DNS-labelled peptides 3-4 were found predominantly in the mitochondrial 
compartment, with a majority of cells scoring positive for colocalization in that organelle (see 
example of compound 3 in Figures 2b, D and E; S4, D and S6, M1). Addition of a lysine 
residue to compound 3 forming compound 4 did not detectably improve the mitochondrial 
distribution (data not shown). With both compounds only some residual lysosomal 
localisation was detected (see example of compound 3 in Figure 2b, I and J, S4, I and S6, 
M1), but no colocalization with the ER compartment was observed (see example of 
compound 3 in Figure 2b, N and O, S4, N and S6, M1). The organelle distribution of the 
ATN-labelled compound 2 was indistinguishable from that of the DNS-peptides (data not 
shown). Nevertheless, despite fulfilling the criteria of selective mitochondria-homing, 
compound 2 was not selected for further development due to its spectral properties (see 
Figure S2, panel a), rendering it impractical to detect microscopically on a routine basis. The 
DNS-peptides were selected for further investigation. 
 
Biological and functional characterization of the iron chelator-peptides 
Our microscopy results with the DNS-peptides prompted the synthesis of compounds 
10 and 13-14, in which the central phenylalanine was replaced by the modified amino acid 
Nε-2.3-dihydroxybenzoyllysine (HBL) and an ornithine-linked 3-hydroxypyridinone chelator 
(Mim) respectively, conferring the resultant peptides with the capability to chelate iron (see 
Figure 1b and Schemes S2 and S3 in Supplementary data ). A control peptide - compound 11, 
lacking iron chelating capability by methylation of one of the phenol groups was also 
prepared (see Figure 1b and Scheme S2 in Supplementary data). While compound 11 mimics 
compound 10 with respect to its biological trafficking (data not shown), it is expected to lack 
iron binding capacity and provides an iron-inert control to demonstrate the utility of 10 as 
iron biosensor. 
The cellular distribution of compounds 10-11 and 13-14 was assessed by fluorescence 
microscopy both qualitatively and quantitatively. The overall analysis revealed that in similar 
fashion to the other DNS-labelled peptides studied –not containing any iron-binding group, 
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compound 13 localizes predominantly in the mitochondria compartment (see Figures 3, D 
and E; S5, D and S6, M1). Similar results were obtained with compounds 10 (see Figures S3, 
S5 and S6, M1 in Supplementary data), 11 and 14 (data not shown). 
The responsiveness of compounds 10-11 and 13-14 to iron was monitored using iron-
specific fluorescence quenching assays. Fluorescent 3-hydroxypyridin-4-one (HPO) 
derivatives have been demonstrated to be selectively quenched in the presence of iron(III), 
iron(II) and copper(II) [36, 37]. However, as the intracellular levels of labile copper(II) are 
typically 10-15 M [38], these molecules are effectively selective for iron under intracellular 
conditions. A novel lysosome-selective fluorescent iron sensor has also been reported where 
the fluorescence was found to be sensitive to the presence of iron(III) and selectively 
quenched by iron(III) in a concentration-dependent manner, both in cell-free systems and in 
cells in culture [36]. We hypothesized that a similar energy transfer mechanism (see Figure 
S7 in Supplementary data) would occur with the proposed mitochondria-selective iron 
sensors 10-11 and 13-14. Indeed, the incremental addition of iron(III) as Fe-NTA (Fe-
nitrilotriacetate) complex to a solution of compound 10 led to the concentration-dependent 
quenching of its fluorescence, with a maximum quenching effect of ca 60% (Figures 4a and 
4e), thereby demonstrating that compound 10 is capable of sensing iron(III) in a cell-free 
system. In contrast, compound 11 showed no responsiveness when incubated with an iron 
solution (Figures 4b and 4e), consistent with its lack of capability to bind iron due to the 
methyl blocking group. These results strongly suggest that the observed decrease in 
fluorescence intensity in compound 10 is solely due to the formation of a complex between 
iron and the chelating catechol moiety. 
Compounds 13-14 were also investigated as described above to assess the effect on 
the iron biosensing activity of the intramolecular chelator-fluorophore distance and iron 
affinity of the chelating group. Compounds 13 and 14 utilise an HPO group as the chelating 
moiety. With a pFe of around 20, such chelators are several orders of magnitude more 
powerful than catechols (pFe ~ 15) [39]. Interestingly, in the group of peptides prepared, 
compound 13 presented the strongest sensitivity towards iron, as revealed by the amplitude of 
fluorescence quenching (ca 100%) (Figures 4c and 4e), against ca 60% for compound 14 
(Figures 4d and 4e) which is similar to the profile of compound 10. 
We assessed the translatability of these findings to FEK4 fibroblast cells, by 
manipulating the intracellular level of iron(III) using Fe(HQ)3 complex and registering the 
effect on the fluorescence of the labelled peptide [40] as described in the Experimental 
section. Addition of as low as 0.2 M Fe(HQ)3 to cells loaded with compound 13 (Figure 5a) 
induced a much sharper decrease in fluorescence when compared to cells loaded with 
compound 10 or 14. After cumulative addition of 3 M iron(III), fluorescence quenching of 
compound 13 reached a plateau at ca 45% of initial fluorescence while quenching of 
compounds 10 and 14 was less marked (ca 15-20% quenching), albeit significant. As 
anticipated, when cells were either not loaded with any peptide, or incubated with the “non-
chelator” control compound 11, fluorescence was not affected by addition of iron. In order to 
ascertain the specificity of the response to LI increase, the cell fluorescence was first 
followed during incremental addition of iron up to a final concentration of 6 M (as detailed 
in the Experimental section). Subsequently, the dequenching of fluorescent signal was 
monitored after addition of a 100 M bolus of the potent iron-specific and membrane-
permeable chelator deferiprone, with the aim to withdraw iron bound to the tested chelator-
peptide localised in the mitochondria. Figure 5b depicts representative fluorescence profiles 
obtained and reveals that all chelator-peptides are responsive to addition of deferiprone. 
Furthermore, effective dequenching could be achieved for all three compounds (35-40 min 
post-addition of deferiprone), demonstrating the iron-dependence of the modulation of 
fluorescence. 
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These data, taken together with the mitochondrial-homing properties of these three 
new compounds successfully demonstrate a proof-of-concept selective delivery to a 
subcellular organelle of an iron chelator capable of registering mitochondrial LIP. 
 
 
DISCUSSION 
 
In an attempt to develop highly specific mitochondria-targeted iron sensors, we first 
investigated the biological trafficking of a series of novel fluorescently labelled SS-like 
peptides to study the effect of the nature and size of the fluorescent probe as well as the 
incorporation of additional lysine residue on their mitochondria-targeting ability. As 
presented in Table 1, compounds 2-9 were essentially fluorescent conjugates of compound 1, 
a model SS peptide which is similar to the reported “SS-02” peptide [24], the radiolabelled 
analogue of which was demonstrated, in cellular studies, to concentrate in mitochondria. 
Based on its sequence, we anticipated that compound 1 will be targeted to mitochondria and 
that any biological perturbation observed in compounds 2-9 will be primarily due to the 
presence of the fluorescent probe. Our cellular distribution data confirmed this prediction. 
Compounds 2-4 were clearly demonstrated to accumulate in mitochondria, whereas 
compounds 5-9 were preferentially cytosolic with some minor colocalization with lysosomes. 
Therefore it appears that the inclusion of ATN or DNS in these model peptides did not 
interfere with their mitochondria-homing properties, whereas the incorporation of either 
DMP or DEP is responsible for the loss of specificity of the peptides for the mitochondria, 
despite their visible uptake by the cells (e.g. Figure 2a B, G and L). Clearly the nature of the 
fluorophore –even if small in size appears to strongly influence the biological function of a 
peptide. Our findings with compound 2 are in agreement with the previously reported ATN- 
conjugated SS peptides [24] demonstrating successful delivery of such fluorescent 
compounds to the mitochondria. ATN is a small and uncharged fluorescent dye, which 
probably explains why it does not disrupt the biological activity of the resulting fluorescent 
peptide when compared to its unlabelled companion (compound 1). We did not investigate 
compound 2 in more detail, despite its mitochondria-selective behaviour, due to its weak 
absorption above 340-350 nm ( max = 315 nm) and low quantum yield rendering it 
unpractical to detect with our microscope equipment. 
The DNS-conjugated peptides are clearly capable of penetrating membranes. We have 
investigated some factors that could contribute to the particular mitochondria tropism of the 
DNS-peptides, guided by the knowledge that the DNS fluorophore is an environment-
sensitive dye [41, 42]. Preliminary biophysical results (see Figures S8 and S9 in 
Supplementary data) on compounds 1 and 3 suggest that the cationic amphipathic peptides 
change conformation upon interaction with membranes supporting the notion that such 
cationic amphipathic sequences can penetrate cell-membranes without the need for a 
transporter or endocytosis [17]. 
The subcellular distribution data further demonstrated that within each group of 
peptides bound to a given fluorophore, the addition of a lysine residue did not have a 
measurable effect on the selectivity for mitochondria. 
These findings have also led to the identification of a lead mitochondria-targeted iron 
chelator. Three DNS-conjugated iron chelator peptides (10, 13 and 14) were selected because 
they were predicted to colocalise with mitochondria. The entire compound series is highly 
hydrophilic (clogD7.4 ≤ -2, Table 1) and the introduction of a chelating centre does not 
appreciably change this value, thus compound 13 has a clogD7.4 value of -2.9, presenting 
multiple positive charges. Such constructs are extremely polar and it will be unlikely that 
such a molecule will remain located in the inner membrane, rather being localized in the 
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matrix. Once inside mitochondria, by virtue of its +6 charge it should remain trapped in the 
aqueous environment, thus sensing the mitochondrial matrix iron levels. The three iron 
chelators 10, 13 and 14 have either catechol or HPO as metal ligands. In both cases the ligand 
has an extremely high-affinity for iron(III), which renders the probes selective for this metal 
under physiological conditions [43]. By virtue of this extremely high affinity for iron(III), 
under aerobic conditions these ligands will rapidly autoxidize iron(II) to generate the stable 
iron(III) complex [44]. Thus all three iron chelators 10, 13 and 14 sense both iron(III) and 
iron(II) in cell-free systems and in cells. Amongst these three iron chelator peptides, the 
HPO-containing compound 13 displayed the highest sensitivity to iron, presumably due to its 
higher affinity for iron(III) [39]. The lower sensitivity of compound 14 compared to 
compound 13 may be due to the longer distance between the fluorophore and the iron 
chelating moiety, resulting in a less efficient energy transfer between those groups upon iron 
binding. Interestingly the maximum amplitude of iron-specific quenching attained for 
compounds 13, 10 and 14 in cell-free systems (i.e. 100, 60 and 60%, respectively) (see Figure 
4e) were higher than those typically obtained in cells (i.e. 45, 20 and 15%, respectively). This 
is likely to be due to the partial quenching of fluorescence during their incubation in cells, 
prior to the addition of Fe(HQ)3, thereby leading to an apparent lower sensitivity. 
Nevertheless the order of sensitivity to iron (i.e. in decreasing order of sensitivity 13 > 10 ~ 
14) was preserved both in the cell-free system and in FEK4 cells, therefore validating the 
cell-free approach to predict sensitivity of this class of compounds in cells. Experiments are 
currently under way which aim at using the above quenching data to determine the 
mitochondrial LI in various cell types and conditions, as well as possible effects of these 
compounds on mitochondrial functions. 
In conclusion, compound 13 is the most promising candidate mitochondrial LI sensor 
of the three compounds we have synthesized. With no adequate mitochondria-specific iron 
sensors available, our compounds are expected to be of significant value to both biological 
and pre-clinical research in the field of iron- and mitochondria-related oxidative injuries and 
pathologies. The use of this mitochondria-targeted iron sensor in physiological and 
pathological conditions characterized by iron-overload in mitochondria is a long-term 
objective currently under investigation in our laboratory.  
 
 
AUTHOR CONTRIBUTIONS 
V.A., O.R., R.C.H. and C.P. conceived and designed the research. V.A. and O.R. performed 
the experiments. V.A., O.R., R.C.H. and C.P. analysed the data. V.A. and O.R. wrote the 
paper with input from R.C.H. and C.P. 
 
 
ACKNOWLEDGMENTS 
We are grateful to Tobias Krams for the Mass Spectrometry analyses and to Dr Tam Bui for 
help and support for CD spectroscopy. We thank Prof. Rex Tyrrell for the gift of FEK4 cells. 
We are also grateful to Prof. David Tosh for allowing us to use his epifluorescence 
microscope, to Dr Adrian Rogers (Microscopy and Analysis Suite, University of Bath), Dr 
Mark Jepson and Mr Alan Leard (Wolfson Bioimaging Facility, University of Bristol) for 
expert help with confocal microscopy. 
 
 
FUNDING 
This work was funded by Biotechnology and Biological Sciences Research Council (BBSRC, 
Grant no BB/J005223/1).  
Ac
ce
pt
d M
an
sc
rip
t
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
    Abbate et al 
10 
 
 
 
REFERENCES 
 
1 Schapira, A. H. V. (2006) Mitochondrial disease. Lancet 368, 70-82. 
2 Vafai, S. B. and Mootha, V. K. (2012) Mitochondrial disorders as windows into an 
ancient organelle. Nature 491, 374-383. 
3 Levi, S. and Rovida, E. (2009) The role of iron in mitochondrial function. Biochim 
Biophys Acta 1790, 629-636. 
4 Cabantchik, Z. I. (2014) Labile iron in cells and body fluids. Physiology, pathology 
and pharmacology. Front. Pharmacol. 5, 1-10. 
5 Winterbourn, C. C. (2008) Reconciling the chemistry and biology of reactive oxygen 
species. Nat Chem Biol. 4, 278-86. 
6 Allen, G. F. G., Toth, R., James, J. and Ganley, I. G. (2013) Loss of iron triggers 
PINK1/Parkin-independent mitophagy. EMBO. Rep. 14, 1127-1135. 
7 Gille, G. and Reichmann, H. (2011) Iron-dependent functions of mitochondria—
relation to neurodegeneration . J. Neural. Transm. 118, 349-359. 
8 Huang, M. L.-H., Becker, E. M., Whitnall, M., Rahmanto, Y. S., Ponka P. and 
Richardson, D. R. (2009) Elucidation of the mechanism of mitochondrial iron loading 
in Friedreich's ataxia by analysis of a mouse mutant. Proc. Natl. Acad. Sci. U.S.A. 
106, 16381-16386. 
9 Isaya, G. (2014) Mitochondrial iron-sulfur cluster dysfunction in neurodegenerative 
disease. Front. Pharmacol. 5, 1-7. 
10 Knight, S. A. B., Sepuri, N. B. V., Pain, D. and Dancis, A. (1998) Mt-Hsp70 
homolog, Ssc2p, required for maturation of yeast frataxin and mitochondrial iron 
homeostasis. J. Biol. Chem. 273, 18389-18393. 
11 Whitnall, M., Rahmanto, Y. S., Huang, M. L.-H., Saletta, F., Lok, H. C., Gutierrez, 
L., Lazaro, F. J., Fleming, A. J., St. Pierre, T. G., Mikhael, M. R., Ponka, P. and 
Richardson, D. R. (2012) Identification of nonferritin mitochondrial iron deposits in a 
mouse model of Friedreich ataxia . Proc. Natl. Acad. Sci. U.S.A. 109, 20590-20595. 
12 Murphy, M. P. and Smith, R. A. J. (2007) Targeting antioxidants to mitochondria by 
conjugation to lipophilic cations . Annu. Rev. Pharmacol. Toxicol. 47, 629-656. 
13 Boddapati, S. V., D'Souza, G. G. M., Erdogan, S., Torchilin, V. P. and Weissig, V. 
(2008) Organelle-targeted nanocarriers: Specific delivery of liposomal ceramide to 
mitochondria enhances its cytotoxicity in vitro and in vivo. Nano. Lett. 8, 2559-2563. 
14 Kelso, G. F., Porteous, C. M., Coulter, C. V., Hughes, G., Porteous, W. K., 
Ledgerwood, E. C., Smith, R. A. J. and Murphy, M. P. (2001) Selective targeting of a 
redox-active ubiquinone to mitochondria within cells - Antioxidant and antiapoptotic 
properties. J. Biol. Chem. 276, 4588-4596. 
15 Murphy, M.P. (2008) Targeting lipophilic cations to mitochondria . Biochim. 
Biophys. Acta-Bioenergetics 1777, 1028-1031. 
16 Rocha, M., Hernandez-Mijares, A., Garcia-Malpartida, K., Banuls, C., Bellod, L. and 
Victor, V.M. (2010) Mitochondria-Targeted Antioxidant Peptides. Curr. Pharm. Des. 
16, 3124-3131. 
17 Szeto, H. H. (2008) Development of Mitochondria-targeted Aromatic-cationic 
Peptides for Neurodegenerative Diseases. Ann. N. Y. Acad. Sci. 1147, 112-121. 
18 Szeto, H. H. and Schiller, P. W. (2011) Novel therapies targeting inner mitochondrial 
membrane-from discovery to clinical development . Pharm. Res. 28, 2669-2679. 
Ac
ce
pte
d M
an
us
cri
pt
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
    Abbate et al 
11 
 
19 Zhao, K., Luo, G. X., Zhao, G. M., Schiller, P. W. and Szeto, H. H. (2003) 
Transcellular transport of a highly polar 3+net charge opioid tetrapeptide. J. 
Pharmacol. Exp. Ther. 304, 425-432. 
20 Berezowska, I., Chung, N. N., Lemieux, C., Zelent, B., Szeto, H. H. and Schiller, P. 
W. (2003) Highly potent fluorescent analogues of the opioid peptide 
[Dmt(1)]DALDA. Peptides 24, 1195-1200. 
21 Zhao, G. M., Qian, X., Schiller, P. W. and Szeto, H. H. (2003) Comparison of 
[Dmt1]DALDA and DAMGO in Binding and G Protein Activation at μ, δ, and κ 
Opioid Receptors. J. Pharmacol. Exp. Ther. 307, 947-954. 
22 Horton, K. L., Stewart, K. M., Fonseca, S. B., Guo, Q. and Kelley, S. O. (2008) 
Mitochondria-penetrating peptides. Chem. Biol. 15, 375-382. 
23 Yousif, L. F., Stewart, K. M., Horton, K. L. and Kelley, S. O. (2009) Mitochondria-
Penetrating Peptides: Sequence Effects and Model Cargo Transport. Chembiochem. 
10, 2081-2088. 
24 Zhao, K., Zhao, G. M., Wu, D., Soong, Y., Birk, A. V., Schiller, P. W. and Szeto, H. 
H. (2004) Cell-permeable peptide antioxidants targeted to inner mitochondrial 
membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. 
J. Biol. Chem. 279, 34682-34690. 
25 Song, W., Shin, J., Lee, J., Kim, H., Oh, D., Edelberg, J. M., Wong, S. C., Szeto, H. 
and Hong, M. K. (2005) A potent opiate agonist protects against myocardial stunning 
during myocardial ischemia and reperfusion in rats. Coron. Artery Dis. 16, 407-410. 
26 Wu, D., Soong, Y., Zhao, G. M. and Szeto, H. H. (2002) A highly potent peptide 
analgesic that protects against ischemia-reperfusion-induced myocardial stunning. 
Am. J. Physiol-Heart Circ. Physiol. 283, H783-H791. 
27 Petri, S., Kiaei, M., Damiano, M., Hiller, A., Wille, E., Manfredi, G., Calingasan, N. 
Y., Szeto, H. H. and Beal, M. F. (2006)  Cell-permeable peptide antioxidants as a 
novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J. 
Neurochem. 98, 1141-1148. 
28 Yang, L., Zhao, K., Calingasan, N. Y., Luo, G., Szeto, H. H., Beal and M. F. (2009) 
Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6- 
tetrahydropyridine neurotoxicity. Antioxid. Redox. Signal. 11, 2095-2104. 
29 Zhao, K., Luo, G. X., Giannelli, S. and Szeto, H. H. (2005) Mitochondria-targeted 
peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl 
hydroperoxide in neuronal cell lines. Biochem. Pharmacol. 70, 1796-1806. 
30 Lei, E. K., Pereira, M. P. and Kelley, S. O. (2013) Tuning the Intracellular Bacterial 
Targeting of Peptidic Vectors. Angew. Chem. Int. Ed. Engl. 52, 9660-9663. 
31 Pereira, M. P. and Kelley, S. O. (2011) Maximizing the Therapeutic Window of an 
Antimicrobial Drug by Imparting Mitochondrial Sequestration in Human Cells. J. 
Am. Chem. Soc. 133, 3260-3263. 
32 Tyrrell, R. M. and Pidoux, M. (1986) Quantitative Differences in Host-Cell 
Reactivation of Ultraviolet-Damaged Virus in Human-Skin Fibroblasts and 
Epidermal-Keratinocytes Cultured from the Same Foreskin Biopsy. Cancer Res. 46, 
2665-2669. 
33 Bolte, S. and Cordelières, F.P. (2006) A guided tour into subcellular colocalization 
analysis in light microscopy. J. Microsc. 224, 213-232. 
34 Manders, E.M.M., Verbeek, F.J. and Aten, J.A. (1993) Measurement of co-
localization of objects in dual-color confocal images. J. Microsc. 169, 375–382. 
35 Dunn, K. W., Kamocka, M. M. and McDonald, J. H. (2011) A practical guide to 
evaluating colocalization in biological microscopy. Am. J. Physiol. Cell Physiol. 300, 
C723‐742. 
Ac
ce
pt
d M
an
us
cri
pt
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
    Abbate et al 
12 
 
36 Fakih, S., Podinovskaia, M., Kong, X., Collins, H. L., Schaible, U. E. and Hider, R.C. 
(2008) Targeting the Lysosome: Fluorescent Iron(III) Chelators To Selectively 
Monitor Endosomal/Lysosomal Labile Iron Pools. J. Med. Chem. 51, 4539-4552. 
37 Luo, W., Ma, Y. M., Quinn, P. J., Hider, R. C. and Liu, Z.D. (2004) Design, synthesis 
and properties of novel iron(III)-specific fluorescent probes. J. Pharm. Pharmacol. 56, 
529-536. 
38 Hider, R. C. and Kong, X. (2013) Iron speciation in the cytosol: an overview. Dalton 
Trans. 42, 3220-3229.  
39 Liu, Z. D. and Hider, R. C. (2002) Design of iron chelators with therapeutic 
application. Coord. Chem. Rev. 232, 151-171. 
40 Ma, Y. M., De Groot, H., Liu, Z. D., Hider, R. C. and Petrat, F. (2006) Chelation and 
determination of labile iron in primary hepatocytes by pyridinone fluorescent probes. 
Biochem. J. 395, 49-55. 
41 Baker, J. G., Middleton, R., Adams, L., May, L. T., Briddon, S. J., Kellam, B. and 
Hill, S. J. (2010) Influence of fluorophore and linker composition on the 
pharmacology of fluorescent adenosine A(1) receptor ligands . Br. J. Pharmacol. 159, 
772-786. 
42 Hohsaka, T., Muranaka, N., Komiyama, C., Matsui, K., Takaura, S., Abe, R., 
Murakami, H. and Sisido, M. (2004) Position-specific incorporation of dansylated 
non-natural amino acids into streptavidin by using a four-base codon. FEBS. Lett. 
560, 173-177. 
43 Zhou, T., Ma, Y., Kong, X. and Hider, R.C. (2012) Design of iron chelators with 
therapeutic application. Dalton Trans. 41, 6371-6389. 
44 Ma, Y., Abbate, V. and Hider, R.C. (2015) Iron-sensitive fluorescent probes: 
monitoring intracellular iron pools. Metallomics. 7, 212-222. 
 
 
FIGURE LEGENDS 
 
Figure 1: (a) Schematic representation of the design of a library of fluorescent “SS-like” 
peptides. (b) Chemical structures of chimeric compounds 10, 11, 13 and 14. 
 
Figure 2: Representative microscopy images of subcellular localization studies of H-F-r-F-
Dap(DMP)-NH2 (compound 5) (a) and H-F-r-F-Dap(DNS)-NH2 (compound 3) (b) in FEK4 
cells with MitoTracker Deep Red-labelled mitochondria (A-E), LysoTracker Deep Red-
labelled lysosomes (F-J) and ER-Tracker Red-labelled ER (K-O). Following incubation with 
the labelled peptide, cells were treated with 1 M MitoTracker, 100 nM LysoTracker or 100 
nM ER-Tracker for 30 min, rinsed and analysed by microscopy. Fluorescence data were 
collected and analysed as described in Experimental section. Green (B, G, L) and red (C, H, 
M) fluorescence data were merged together (D, I, N) to identify colocalization in yellow. 
Inserts (E, J, O) are representative of a magnified region from the merged picture. Phase 
contrast images (A, F, K) corresponding to the fluorescence data are also shown. 
 
Figure 3: Representative microscopy images of subcellular localization studies of DNS-
labelled peptide H-F-r-Mim-Dap(DNS)-NH2 (compound 13) with mitochondrial (A-E), 
lysosomal (F-J) and ER (K-O) compartments, performed as described in Experimental 
section. 
 
Figure 4: Fluorescence intensity profiles as a function of increasing concentrations (0-5 M 
range) of iron(III) for compounds 10 (a), 11 (b), 13 (c) and 14 (d). Plot of percentage of 
Ac
c
pte
d M
an
sc
rip
t
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
    Abbate et al 
13 
 
fluorescence quenching (mean +/- STD of three independent observations) as a function of 
increasing iron(III) concentrations (e). 
 
Figure 5: Fluorescence quenching and dequenching of compounds 10, 11, 13 and 14 in 
FEK4 cells in response to the manipulation of cellular levels of iron. Cells incubated (or not) 
with peptide were loaded with iron(III) in the form of Fe(HQ)3 as described in Experimental 
section and then treated with a bolus of 100 M of the iron-specific chelator deferiprone. A 
representative experiment is depicted for each compound. Plots of fluorescence as a function 
of total iron(III) concentration added (a) and as a function of time (b). 
 
 
 
 
 
 
Table 1: Sequence and physicochemical properties of compounds 1-9. 
 
Compound Sequence 1 MW pKa values (calculated) 2 
clogD 7.4 2 
Net charge
(pH 7.4) 3 
1 H-F-r-F-Dap-NH2 553.31   7.54; 11.67; 8.09 -5.4 +2.3 
2 H-F-r-F-Dap(ATN)-NH2 672.78   7.68; 12.12; 2.70 -3.1 + 1.7 
3 H-F-r-F-Dap(DNS)-NH2 786.94   7.68; 12.00; 9.90; 4.63 -5.2 + 1.7 
4 H-F-r-F-K-Dap(DNS)-NH2 915.11   7.68; 11.94; 10.35; 9.72; 4.63 -1.9 + 2.7 
5 H-F-r-F-Dap(DMP)-NH2 782.89   7.68; 11.58; 3.36 -6.5 + 1.7 
6 H-F-r-F-K-Dap(DMP)-NH2 911.06   7.68; 11.53; 10.18; 3.36 -3.3 + 2.7 
7 H-F-r-F-K-(DMP)-NH2 824.97   7.68; 11.70; 3.36 -2.2 + 1.7 
8 H-F-r-F-K-Dap(DEP)-NH2 925.09   7.68; 11.51; 10.18; 4.16 -5.7 + 2.7 
9 H-F-r-F-Dap(DEP)-NH2 796.91   7.68; 11.55; 4.16 -2.4 + 1.7 
 
1
 Fluorophore indicated in parentheses. L-amino acids in capital letters; D-amino acids in 
lower letters. All the peptides present C-amidation. 
2
 The pKa and clogD7.4 values were calculated using MarvinView 6.1.3. 
3
 The net charge values were obtained using the calculated pKa values as reference using 
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